Cargando…

The baseline metabolism parameters of (18)F‑FDG PET/CT as promising prognostic biomarkers in pediatric Langerhans cell histiocytosis

BACKGROUND: Langerhans cell histiocytosis (LCH) is a rare myeloid precursor cell inflammatory neoplasia, which agonizes, maims, and even kills patients. Although clinical outcomes have steadily improved over the past decades, the progression/relapse rate of LCH remains high. The purpose of this stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Xia, Wei, Ang, Wang, Guanyun, Du, Junye, Feng, Lijuan, Ou, Wenxin, Wang, Tianyou, Wang, Wei, Li, Jixia, Zhang, Mingyu, Zhang, Rui, Yang, Jigang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10498231/
https://www.ncbi.nlm.nih.gov/pubmed/37711802
http://dx.doi.org/10.21037/qims-23-290
_version_ 1785105475344269312
author Lu, Xia
Wei, Ang
Wang, Guanyun
Du, Junye
Feng, Lijuan
Ou, Wenxin
Wang, Tianyou
Wang, Wei
Li, Jixia
Zhang, Mingyu
Zhang, Rui
Yang, Jigang
author_facet Lu, Xia
Wei, Ang
Wang, Guanyun
Du, Junye
Feng, Lijuan
Ou, Wenxin
Wang, Tianyou
Wang, Wei
Li, Jixia
Zhang, Mingyu
Zhang, Rui
Yang, Jigang
author_sort Lu, Xia
collection PubMed
description BACKGROUND: Langerhans cell histiocytosis (LCH) is a rare myeloid precursor cell inflammatory neoplasia, which agonizes, maims, and even kills patients. Although clinical outcomes have steadily improved over the past decades, the progression/relapse rate of LCH remains high. The purpose of this study was to evaluate the prognostic value of the pre-treatment metabolism parameters of baseline (18)F-fluorodeoxyglucose positron emission tomography/computed tomography ((18)F‑FDG PET/CT) in children with LCH. METHODS: This cross-sectional study retrospectively and consecutively included 37 children (24 males and 13 females; median age, 5.1 years; range, 2.4–7.8 years) with pre-treatment (18)F-FDG PET/CT from September 2020 to September 2022 in Nuclear Medicine Department, Beijing friendship hospital, Capital Medical University, Beijing, China. These patients were then all admitted to the hospital and diagnosed with LCH by biopsy, in Hematology Center, Beijing Children’s Hospital, Capital Medical University, Beijing, China. Five metabolism parameters of (18)F-FDG PET/CT were analyzed, including maximum standardized uptake, tumor-to-normal liver standard uptake value ratio, tumor-to-normal bone marrow standard uptake value ratio, sum of metabolic tumor volume (sMTV), and sum of total lesion glycolysis (sTLG) of all lesions. Patients were followed up for at least 1 year or until disease progression/relapse. Univariate and multivariate analyses of progression-free survival was performed. RESULTS: During follow-up, 11 (29.7%) patients had disease progression/relapse. Univariate analysis revealed that the risk organ involvement, the treatment response at the 5(th) or 11(th) week, pre-treatment sMTV, and sTLG were significantly associated with progression-free survival (P=0.024, 0.018, 0.006, 0.006, and 0.042, respectively). Multivariate COX analysis revealed that non-response at the 11(th) week, pre-treatment sMTV >32.55 g/cm(3), and sTLG >98.86 g (P=0.002, 0.020, 0.026, respectively) were risk factors for progression-free survival. CONCLUSIONS: The baseline metabolism parameters of (18)F-FDG PET/CT could be promising imaging biomarkers for predicting prognosis in children with LCH.
format Online
Article
Text
id pubmed-10498231
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-104982312023-09-14 The baseline metabolism parameters of (18)F‑FDG PET/CT as promising prognostic biomarkers in pediatric Langerhans cell histiocytosis Lu, Xia Wei, Ang Wang, Guanyun Du, Junye Feng, Lijuan Ou, Wenxin Wang, Tianyou Wang, Wei Li, Jixia Zhang, Mingyu Zhang, Rui Yang, Jigang Quant Imaging Med Surg Original Article BACKGROUND: Langerhans cell histiocytosis (LCH) is a rare myeloid precursor cell inflammatory neoplasia, which agonizes, maims, and even kills patients. Although clinical outcomes have steadily improved over the past decades, the progression/relapse rate of LCH remains high. The purpose of this study was to evaluate the prognostic value of the pre-treatment metabolism parameters of baseline (18)F-fluorodeoxyglucose positron emission tomography/computed tomography ((18)F‑FDG PET/CT) in children with LCH. METHODS: This cross-sectional study retrospectively and consecutively included 37 children (24 males and 13 females; median age, 5.1 years; range, 2.4–7.8 years) with pre-treatment (18)F-FDG PET/CT from September 2020 to September 2022 in Nuclear Medicine Department, Beijing friendship hospital, Capital Medical University, Beijing, China. These patients were then all admitted to the hospital and diagnosed with LCH by biopsy, in Hematology Center, Beijing Children’s Hospital, Capital Medical University, Beijing, China. Five metabolism parameters of (18)F-FDG PET/CT were analyzed, including maximum standardized uptake, tumor-to-normal liver standard uptake value ratio, tumor-to-normal bone marrow standard uptake value ratio, sum of metabolic tumor volume (sMTV), and sum of total lesion glycolysis (sTLG) of all lesions. Patients were followed up for at least 1 year or until disease progression/relapse. Univariate and multivariate analyses of progression-free survival was performed. RESULTS: During follow-up, 11 (29.7%) patients had disease progression/relapse. Univariate analysis revealed that the risk organ involvement, the treatment response at the 5(th) or 11(th) week, pre-treatment sMTV, and sTLG were significantly associated with progression-free survival (P=0.024, 0.018, 0.006, 0.006, and 0.042, respectively). Multivariate COX analysis revealed that non-response at the 11(th) week, pre-treatment sMTV >32.55 g/cm(3), and sTLG >98.86 g (P=0.002, 0.020, 0.026, respectively) were risk factors for progression-free survival. CONCLUSIONS: The baseline metabolism parameters of (18)F-FDG PET/CT could be promising imaging biomarkers for predicting prognosis in children with LCH. AME Publishing Company 2023-08-04 2023-09-01 /pmc/articles/PMC10498231/ /pubmed/37711802 http://dx.doi.org/10.21037/qims-23-290 Text en 2023 Quantitative Imaging in Medicine and Surgery. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Lu, Xia
Wei, Ang
Wang, Guanyun
Du, Junye
Feng, Lijuan
Ou, Wenxin
Wang, Tianyou
Wang, Wei
Li, Jixia
Zhang, Mingyu
Zhang, Rui
Yang, Jigang
The baseline metabolism parameters of (18)F‑FDG PET/CT as promising prognostic biomarkers in pediatric Langerhans cell histiocytosis
title The baseline metabolism parameters of (18)F‑FDG PET/CT as promising prognostic biomarkers in pediatric Langerhans cell histiocytosis
title_full The baseline metabolism parameters of (18)F‑FDG PET/CT as promising prognostic biomarkers in pediatric Langerhans cell histiocytosis
title_fullStr The baseline metabolism parameters of (18)F‑FDG PET/CT as promising prognostic biomarkers in pediatric Langerhans cell histiocytosis
title_full_unstemmed The baseline metabolism parameters of (18)F‑FDG PET/CT as promising prognostic biomarkers in pediatric Langerhans cell histiocytosis
title_short The baseline metabolism parameters of (18)F‑FDG PET/CT as promising prognostic biomarkers in pediatric Langerhans cell histiocytosis
title_sort baseline metabolism parameters of (18)f‑fdg pet/ct as promising prognostic biomarkers in pediatric langerhans cell histiocytosis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10498231/
https://www.ncbi.nlm.nih.gov/pubmed/37711802
http://dx.doi.org/10.21037/qims-23-290
work_keys_str_mv AT luxia thebaselinemetabolismparametersof18ffdgpetctaspromisingprognosticbiomarkersinpediatriclangerhanscellhistiocytosis
AT weiang thebaselinemetabolismparametersof18ffdgpetctaspromisingprognosticbiomarkersinpediatriclangerhanscellhistiocytosis
AT wangguanyun thebaselinemetabolismparametersof18ffdgpetctaspromisingprognosticbiomarkersinpediatriclangerhanscellhistiocytosis
AT dujunye thebaselinemetabolismparametersof18ffdgpetctaspromisingprognosticbiomarkersinpediatriclangerhanscellhistiocytosis
AT fenglijuan thebaselinemetabolismparametersof18ffdgpetctaspromisingprognosticbiomarkersinpediatriclangerhanscellhistiocytosis
AT ouwenxin thebaselinemetabolismparametersof18ffdgpetctaspromisingprognosticbiomarkersinpediatriclangerhanscellhistiocytosis
AT wangtianyou thebaselinemetabolismparametersof18ffdgpetctaspromisingprognosticbiomarkersinpediatriclangerhanscellhistiocytosis
AT wangwei thebaselinemetabolismparametersof18ffdgpetctaspromisingprognosticbiomarkersinpediatriclangerhanscellhistiocytosis
AT lijixia thebaselinemetabolismparametersof18ffdgpetctaspromisingprognosticbiomarkersinpediatriclangerhanscellhistiocytosis
AT zhangmingyu thebaselinemetabolismparametersof18ffdgpetctaspromisingprognosticbiomarkersinpediatriclangerhanscellhistiocytosis
AT zhangrui thebaselinemetabolismparametersof18ffdgpetctaspromisingprognosticbiomarkersinpediatriclangerhanscellhistiocytosis
AT yangjigang thebaselinemetabolismparametersof18ffdgpetctaspromisingprognosticbiomarkersinpediatriclangerhanscellhistiocytosis
AT luxia baselinemetabolismparametersof18ffdgpetctaspromisingprognosticbiomarkersinpediatriclangerhanscellhistiocytosis
AT weiang baselinemetabolismparametersof18ffdgpetctaspromisingprognosticbiomarkersinpediatriclangerhanscellhistiocytosis
AT wangguanyun baselinemetabolismparametersof18ffdgpetctaspromisingprognosticbiomarkersinpediatriclangerhanscellhistiocytosis
AT dujunye baselinemetabolismparametersof18ffdgpetctaspromisingprognosticbiomarkersinpediatriclangerhanscellhistiocytosis
AT fenglijuan baselinemetabolismparametersof18ffdgpetctaspromisingprognosticbiomarkersinpediatriclangerhanscellhistiocytosis
AT ouwenxin baselinemetabolismparametersof18ffdgpetctaspromisingprognosticbiomarkersinpediatriclangerhanscellhistiocytosis
AT wangtianyou baselinemetabolismparametersof18ffdgpetctaspromisingprognosticbiomarkersinpediatriclangerhanscellhistiocytosis
AT wangwei baselinemetabolismparametersof18ffdgpetctaspromisingprognosticbiomarkersinpediatriclangerhanscellhistiocytosis
AT lijixia baselinemetabolismparametersof18ffdgpetctaspromisingprognosticbiomarkersinpediatriclangerhanscellhistiocytosis
AT zhangmingyu baselinemetabolismparametersof18ffdgpetctaspromisingprognosticbiomarkersinpediatriclangerhanscellhistiocytosis
AT zhangrui baselinemetabolismparametersof18ffdgpetctaspromisingprognosticbiomarkersinpediatriclangerhanscellhistiocytosis
AT yangjigang baselinemetabolismparametersof18ffdgpetctaspromisingprognosticbiomarkersinpediatriclangerhanscellhistiocytosis